• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Acute HIV Infection Presenting With Diffuse Plaque Psoriasis Treated With Highly Active Antiretroviral Therapy.急性HIV感染伴弥漫性斑块状银屑病经高效抗逆转录病毒治疗。
Cureus. 2021 Nov 17;13(11):e19680. doi: 10.7759/cureus.19680. eCollection 2021 Nov.
2
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯固定剂量复方片与多替拉韦加拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初治：96 周随机、双盲、多中心、3 期、非劣效性试验结果。
Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.
3
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯复方片剂与多替拉韦加拉米夫定和丙酚替诺福韦二吡呋酯用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1490）：一项随机、双盲、多中心、3 期、非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.
4
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.比克替拉韦与多替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯用于 HIV-1 感染初始治疗的双盲、随机、2 期临床试验
Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.
5
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.从多替拉韦加阿巴卡韦和拉米夫定转换为固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺治疗病毒学抑制的 HIV-1 成人患者：一项随机、双盲、多中心、活性对照、3 期、非劣效性临床试验的 48 周结果。
Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18.
6
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.在病毒学抑制的 HIV-1 成人中，从基于增效蛋白酶抑制剂的方案转换为固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺的疗效和安全性：一项随机、开放标签、多中心、3 期、非劣效性试验的 48 周结果。
Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18.
7
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.固定剂量复方比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺与含多替拉韦方案治疗初治人类免疫缺陷病毒 1 型感染：两项随机、双盲、多中心、Ⅲ期、非劣效性临床试验的 144 周结果。
Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0.
8
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.固定剂量复方双替格瑞韦、恩曲他滨和替诺福韦艾拉酚胺在青少年和儿童 HIV 感染者中的应用：一项单臂、开放标签、多中心、2/3 期临床试验的第 48 周结果。
Lancet Child Adolesc Health. 2021 Sep;5(9):642-651. doi: 10.1016/S2352-4642(21)00165-6. Epub 2021 Jul 22.
9
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺：用于治疗 HIV-1 感染的药物。
Drugs. 2018 Nov;78(17):1817-1828. doi: 10.1007/s40265-018-1010-7.
10
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.在初始使用比克替拉韦、恩曲他滨/丙酚替诺福韦或多替拉韦/恩曲他滨/丙酚替诺福韦治疗后，换用比克替拉韦/恩曲他滨/丙酚替诺福韦复方制剂。
AIDS. 2018 Jul 31;32(12):1723-1725. doi: 10.1097/QAD.0000000000001894.

本文引用的文献

1
HIV-associated psoriasis: Epidemiology, pathogenesis, and management.HIV 相关性银屑病：流行病学、发病机制与治疗。
Dermatol Ther. 2019 Mar;32(2):e12806. doi: 10.1111/dth.12806. Epub 2019 Jan 6.
2
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections.银屑病：哪种疗法适合哪种患者：关注特殊人群和慢性感染。
J Am Acad Dermatol. 2019 Jan;80(1):43-53. doi: 10.1016/j.jaad.2018.06.056. Epub 2018 Jul 11.
3
T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities.银屑病发病机制及相关心血管合并症中的T细胞层级结构
Front Immunol. 2018 Jun 19;9:1390. doi: 10.3389/fimmu.2018.01390. eCollection 2018.
4
Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.HIV阳性患者的银屑病治疗：系统性免疫抑制疗法的系统评价
Cutis. 2018 Jan;101(1):38;42;56.
5
Psoriasis prevalence among adults in the United States.美国成年人银屑病患病率。
J Am Acad Dermatol. 2014 Mar;70(3):512-6. doi: 10.1016/j.jaad.2013.11.013. Epub 2014 Jan 2.
6
Particular clinical presentations of psoriasis in HIV patients.HIV患者银屑病的特殊临床表现。
Int J STD AIDS. 2011 Nov;22(11):653-4. doi: 10.1258/ijsa.2011.010525.
7
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.HIV 感染者中的银屑病：来自全国银屑病基金会医学委员会。
J Am Acad Dermatol. 2010 Feb;62(2):291-9. doi: 10.1016/j.jaad.2009.03.047. Epub 2009 Jul 31.
8
Cutaneous markers of HIV infection.
Clin Dermatol. 2004 Nov-Dec;22(6):487-98. doi: 10.1016/j.clindermatol.2004.07.007.

急性HIV感染伴弥漫性斑块状银屑病经高效抗逆转录病毒治疗。

Acute HIV Infection Presenting With Diffuse Plaque Psoriasis Treated With Highly Active Antiretroviral Therapy.

作者信息

Bressler Moshe Y, Pathak Naeha, Rotblat David, Tamez Rebecca

机构信息

Dermatology, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, USA.

Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA.

出版信息

Cureus. 2021 Nov 17;13(11):e19680. doi: 10.7759/cureus.19680. eCollection 2021 Nov.

DOI:10.7759/cureus.19680
PMID:34976468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8681926/
Abstract

Cutaneous diseases such as psoriasis are often the first disease manifestations in HIV+ patients, with greater severity corresponding to a weaker immune system. Despite its prevalence, literature and placebo-controlled studies on the recognition of HIV as a cause of psoriasis are lacking, causing challenges to arise in its treatment. In this article, we illustrate a case of an HIV+ patient whose psoriasis drastically improved after the initiation of highly active antiretroviral therapy (HAART) consisting of bictegravir, emtricitabine, and tenofovir alafenamide. While it is unclear which combination of antiretrovirals is optimal for controlling psoriasis in HIV+ patients, prompt initiation of HAART can significantly improve immune status and psoriasis in HIV+ patients.

摘要

银屑病等皮肤病往往是HIV阳性患者最早出现的疾病表现，病情越严重表明免疫系统越弱。尽管其发病率很高，但缺乏关于将HIV认定为银屑病病因的文献和安慰剂对照研究，这给其治疗带来了挑战。在本文中，我们阐述了一例HIV阳性患者的病例，该患者在开始使用由比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺组成的高效抗逆转录病毒疗法（HAART）后，银屑病病情大幅改善。虽然尚不清楚哪种抗逆转录病毒药物组合对控制HIV阳性患者的银屑病最为理想，但及时启动HAART可显著改善HIV阳性患者的免疫状态和银屑病病情。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fba/8681926/e63fec885f1e/cureus-0013-00000019680-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fba/8681926/f5ef7ca245ce/cureus-0013-00000019680-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fba/8681926/e63fec885f1e/cureus-0013-00000019680-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fba/8681926/f5ef7ca245ce/cureus-0013-00000019680-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fba/8681926/e63fec885f1e/cureus-0013-00000019680-i02.jpg